Opus Genetics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Balyasny Asset Management L.P. and affiliated entities have reported a beneficial ownership stake of 6.64% in Opus Genetics Inc., indicating a shift in institutional holding.
NASDAQ
Perceptive Advisors and Joseph Edelman have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Opus Genetics, Inc.
NASDAQ
Caligan Partners LP and David Johnson have reported beneficial ownership of 8.5% of Opus Genetics, Inc. common stock as of March 31, 2026.
NASDAQ
Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 7.18% of Opus Genetics Inc. common stock as of March 31, 2026.
NASDAQ
Several Bios-affiliated entities and individuals have reported a combined beneficial ownership of 4.53% in Opus Genetics, Inc. common stock.
NASDAQ
Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has filed a Schedule 13G, reporting beneficial ownership of 8.47% of Opus Genetics, Inc. common stock as of March 31, 2026.
NASDAQ
Balyasny Asset Management and its affiliates have reported a 7.41% beneficial ownership stake in Opus Genetics Inc., totaling 5,110,373 shares.
NASDAQ
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Opus Genetics, Inc., including shares acquirable via warrants.
NASDAQ
SCHEDULE 13G/A: Nantahala Capital Boosts Opus Genetics Stake to 9.99%
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership in Opus Genetics, Inc. as of June 30, 2025.
NASDAQ
A group of Bios-affiliated funds and individuals have jointly reported a beneficial ownership of 6.2% in Opus Genetics, Inc. common stock.
NASDAQ
Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, have reported a beneficial ownership of 9.99% in Opus Genetics, Inc.'s common stock as of March 31, 2025.
NASDAQ
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a 9.99% beneficial ownership stake in Opus Genetics, Inc. through a Schedule 13G filing.